专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240077497A1 METHODS FOR THE DETECTION OF ANTI-DRUG ANTIBODIES AGAINST FACTOR XI AND/OR FACTOR XIA ANTIBODIES 审中-公开
公开(公告)号：US20240077497A1
公开(公告)日：2024-03-07
申请号：US18335507
申请日：2023-06-15
申请人： Anthos Therapeutics, Inc.
发明人： Debra A. FREEDHOLM , Daniel M. BLOOMFIELD , Royston J. GLASSPOOL , Jonathan E. FREEMAN , Yasser KHDER
IPC分类号： G01N33/68 , G01N33/86
CPC分类号： G01N33/686 , G01N33/86 , G01N2333/96452 , G01N2800/52
摘要： This disclosure relates to methods for detection and measurement of anti-drug antibodies (ADAs) against Factor XI and/or Factor XIa therapeutic antibodies, e.g., in a subject being treated with said Factor XI and/or Factor XIa therapeutic antibodies.

2. 发明申请

US20170321218A1 FACTOR XIA-SPECIFIC APTAMERS 审中-公开
公开(公告)号：US20170321218A1
公开(公告)日：2017-11-09
申请号：US15586581
申请日：2017-05-04
申请人： CANADIAN BLOOD SERVICES
发明人： William Peter Sheffield , David Apraku Donkor
IPC分类号： C12N15/113 , G01N33/86 , A61K49/00
CPC分类号： C12N15/1137 , A61K49/0004 , C12N15/115 , C12N2310/16 , C12Y304/21027 , G01N33/86 , G01N2333/96452
摘要： The present disclosure concerns aptamers of formula (I) capable of specifically binding to Factor XIa. The aptamers can be used to prevent, treat or alleviate the symptoms of thrombosis. The aptamers can also be used to detect Factor XIa in a sample and/or purify Factor XIa from a sample. The aptamers can further be used to identity putative therapeutic agents for the prevention, treatment or alleviation of symptoms associated with thrombosis.

3. 发明授权

US4882272A High molecular weight kininogen assay 失效
标题翻译：高分子量激肽原测定
公开(公告)号：US4882272A
公开(公告)日：1989-11-21
申请号：US11963
申请日：1987-02-06
申请人： Cheryl F. Scott , Robert W. Colman
发明人： Cheryl F. Scott , Robert W. Colman
IPC分类号： C12Q1/56
CPC分类号： C12Q1/56 , C12Q2337/12 , C12Q2337/22 , G01N2333/96452 , G01N2333/96458
摘要： An assay for functional high molecular weight kininogen in plasma is provided. A plasma sample of unknown functional high molecular kininogen content is treated to inactivate plasma protease inhibitors and kallikrein, and is appropriately neutralized and diluted. Exogenous factor XIIa and factor XI are added to the sample to form a reaction mixture which is incubated with a contact-activating surface. The concentrations of factor XIIa and factor XI in the reaction mixture are selected such that the concentration of functional high molecular weight kininogen in the sample is rate-limiting in the HMWK-mediated activation of factor XI by factor XIIa. The amount of factor XIa generated in the sample, which under the conditions of the assay is directly proportional to the concentration of functional HMWK, may be determined by functional assay using an appropriate factor XIa substrate.
摘要翻译：提供血浆中功能性高分子量激肽原的测定法。处理未知功能性高分子激肽原含量的血浆样品以灭活血浆蛋白酶抑制剂和激肽释放酶，并被适当中和和稀释。将外源因子XIIa和因子XI加入到样品中以形成与接触激活表面一起温育的反应混合物。选择反应混合物中因子XIIa和因子XI的浓度，使得样品中功能性高分子量激肽原的浓度在通过因子XIIa的HMWK介导的因子XI的激活中是速率限制的。样品中产生的因子XIa的量，其在测定条件下与功能性HMWK的浓度成正比，可以通过使用适当因子XIa底物的功能测定来确定。

4. 发明公开

US20230314454A1 BLOOD COAGULATION TEST REAGENT, AND BLOOD COAGULATION TEST METHOD 审中-公开
公开(公告)号：US20230314454A1
公开(公告)日：2023-10-05
申请号：US18329833
申请日：2023-06-06
申请人： Thrombo Translational Research Lab Inc.
发明人： Yuichi KAMIKUBO
IPC分类号： G01N33/86 , C07K14/745
CPC分类号： G01N33/86 , C07K14/745 , G01N2333/974 , G01N2333/96452 , G01N2333/7454
摘要： A highly sensitive blood coagulation test reagent that enables determining and evaluating bleeding risk of direct oral anticoagulants (DOACs) and the like accurately in hemorrhagic diseases, and the like are provided. A blood coagulation test reagent containing: an active form of a blood coagulation factor XI (FXIa); and tissue factor (TF). A blood coagulation test method including a step of measuring the amount of thrombin generated by reacting a biological sample as a test specimen with a test reagent containing: 0.5 pM to 1,000 pM of an active form of a blood coagulation factor XI(FXIa); and 1 fM to 1,000 fM of tissue factor.

5. 发明授权

US10494634B2 Factor XIa-specific aptamers 有权
公开(公告)号：US10494634B2
公开(公告)日：2019-12-03
申请号：US15586581
申请日：2017-05-04
申请人： CANADIAN BLOOD SERVICES
发明人： William Peter Sheffield , David Apraku Donkor
IPC分类号： C07H21/04 , C12N15/113 , A61K49/00 , G01N33/86 , C12N15/115
CPC分类号： C12N15/1137 , A61K49/0004 , C12N15/115 , C12Y304/21027 , G01N33/86 , C12N2310/16 , G01N2333/96452
摘要： The present disclosure concerns aptamers of formula (I) capable of specifically binding to Factor XIa. The aptamers can be used to prevent, treat or alleviate the symptoms of thrombosis. The aptamers can also be used to detect Factor XIa in a sample and/or purify Factor XIa from a sample. The aptamers can further be used to identity putative therapeutic agents for the prevention, treatment or alleviation of symptoms associated with thrombosis.

6. 发明申请

US20150240287A1 METHOD FOR EVALUATING BLOOD COAGULATION REACTION 审中-公开
标题翻译：评估血液凝聚反应的方法
公开(公告)号：US20150240287A1
公开(公告)日：2015-08-27
申请号：US14431425
申请日：2013-09-26
申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA , PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY
发明人： Tetsuhiro Soeda , Takehisa Kitazawa , Midori Shima
IPC分类号： C12Q1/56 , C12N9/64
CPC分类号： C12Q1/56 , C12N9/6443 , G01N33/86 , G01N2333/755 , G01N2333/96452 , G01N2800/224
摘要： Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.
摘要翻译：研究了各种评价止血效果的方法和各种血液凝固起始试剂，构建了用具有代替凝血因子VIII（FVIII）的物质介导的血液凝固反应的评价方法。结果发现，通过使用含有活化凝血因子XI（FXIa）和磷脂的凝血起始试剂，可以使用具有代替凝血因子VIII（FVIII）的活性的物质对凝血反应的作用，使用在血液样品中产生的凝血酶量作为指标。

7. 发明授权

US5627038A Factor IX chromogenic assay 失效
标题翻译：因子IX显色测定
公开(公告)号：US5627038A
公开(公告)日：1997-05-06
申请号：US322970
申请日：1994-10-13
申请人： H. C. Hemker
发明人： H. C. Hemker
IPC分类号： C12Q1/37 , C12Q1/56 , G01N33/53
CPC分类号： C12Q1/56 , C12Q2337/12 , G01N2333/96444 , G01N2333/9645 , G01N2333/96452 , Y10S435/966 , Y10S435/975 , Y10S436/808
摘要： A chromogenic assay for determination of blood coagulation Factor IX (christmas factor) utilizes Factor Xa formed by the conversion of Factor X by activated Factor IX and Factor VIII to cleave a chromogenic substrate. The sample is combined into a mixture with Factor XIa in the presence of Factor IIa (thrombin), incubated, combined with Factor X and Factor VIII, and incubated. A thrombin inhibitor, and an indicator agent which reacts with Factor Xa, are added and the resulting signal measured and correlated to the level of Factor IX in the sample.
摘要翻译：用于测定血液凝固因子IX（圣诞节因子）的显色测定利用通过活化因子IX和因子VIII转化因子X形成的因子Xa，以切割显色底物。在因子IIa（凝血酶）存在下将样品与因子XIa混合，孵育，与因子X和因子VIII组合，并孵育。加入凝血酶抑制剂和与因子Xa反应的指示剂，并测量所得信号并与样品中因子IX的水平相关。

8. 发明授权

US4257939A Peptide derivative 失效
标题翻译：肽衍生物
公开(公告)号：US4257939A
公开(公告)日：1981-03-24
申请号：US87922
申请日：1979-10-25
申请人： Shumpei Sakakibara
发明人： Shumpei Sakakibara
IPC分类号： G01N33/68 , C07D311/16 , C07K5/06 , C07K5/08 , C07K5/083 , C07K5/087 , C12Q1/37 , C12Q1/56 , C07C103/52
CPC分类号： C12Q1/56 , C07D311/16 , C07K5/06043 , C07K5/0606 , C07K5/0808 , C07K5/0812 , C12Q1/37 , C12Q2337/12 , C12Q2337/22 , G01N2333/96452 , Y02P20/55 , Y10S530/802
摘要： A peptide derivative useful as substrates for determining enzymatic activities have the following formula ##STR1## wherein R.sub.1 is a group selected from the group consisting of seryl, phenylalanyl-seryl, threonyl and leucyl-threonyl groups, and R.sub.2 is ##STR2##
摘要翻译：可用作测定酶活性的底物的肽衍生物具有下式：其中R1是选自丝氨酰基，苯丙氨酰 - 丝氨酰基，苏氨酰基和亮氨酰 - 苏氨酰基的基团，R2是

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式